Increlex

Mecasermin, the active ingredient in Increlex, is a recombinant human insulin-like growth factor-1 presented as an injection solution for subcutaneous use. It treats severe primary insulin-like growth factor-1 (IGF-1) deficiency and growth failure due to growth hormone gene deletion in pediatric patients.

GNH USA supplies Increlex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and specialized care centres worldwide. The company adheres to stringent quality standards and regulatory requirements to ensure product integrity. Clients benefit from reliable cold‑chain logistics and dedicated technical support.

Increlex (mecasermin) is used in the IGF‑1 deficiency pathway to promote linear growth in children with specific endocrine disorders. - Severe primary IGF‑1 deficiency: replaces deficient IGF‑1, helping to normalize growth velocity and improve height outcomes in affected children. - Growth failure due to growth hormone gene deletion: provides exogenous IGF‑1 to bypass the absent GH signal, facilitating linear growth in patients with GH‑gene mutations. - Confirmed IGF‑1 deficiency unresponsive to growth hormone therapy: offers an alternative pathway to stimulate growth when GH treatment is ineffective.

Mecasermin may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Injection site reactions: redness, swelling or pain at the injection site. - Hypoglycemia: low blood glucose, especially when administered without adequate carbohydrate intake. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal discomfort. - Peripheral edema: swelling of limbs. - Joint pain: arthralgia reported in some patients.

Serious or Rare Side Effects: - Intracranial hypertension: signs include headache, visual changes, vomiting; requires immediate medical attention. - Allergic reactions: rash, urticaria, or anaphylaxis in rare cases. - Elevated intracranial pressure leading to papilledema.

When prescribing mec asermin, clinicians should consider several precautionary measures to ensure safe use. - Dose titration: start with low dose and adjust based on IGF‑1 levels and growth response. - Blood glucose monitoring: regularly check glucose to detect hypoglycemia. - Intracranial pressure monitoring: observe for signs of increased pressure, especially in patients with pre‑existing conditions. - Allergy assessment: screen for prior hypersensitivity to recombinant proteins. - Long‑term growth surveillance: track height velocity and skeletal maturation. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mecasermin can interact with other agents that affect glucose metabolism or share similar pathways.

Major Interactions (Avoid): - Insulin: concurrent use may cause severe hypoglycemia; dose adjustments required. - Oral hypoglycemic agents (e.g., sulfonylureas): increased risk of low blood sugar.

Moderate Interactions (Monitor Closely): - Glucocorticoids: may blunt IGF‑1 response, requiring dose modification. - Thyroid hormone replacement: altered metabolism may affect growth outcomes. - Growth hormone therapy: overlapping effects may necessitate careful monitoring.